货号	规格	价格	上海	北京	珠海	重庆	武汉
V48717-5mg	≥90%	￥2390.00 V48717-5mg ￥2390.00 3-5天	0 货期：3-5天	-	-	-	-
V48717-10mg	≥90%	￥3830.00 V48717-10mg ￥3830.00 3-5天	0 货期：3-5天	-	-	-	-
V48717-25mg	≥90%	￥6880.00 V48717-25mg ￥6880.00 3-5天	0 货期：3-5天	-	-	-	-
V48717-50mg	≥90%	￥11000.00 V48717-50mg ￥11000.00 3-5天	0 货期：3-5天	-	-	-	-
V48717-100mg	≥90%	￥17600.00 V48717-100mg ￥17600.00 3-5天	0 货期：3-5天	-	-	-	-

大包装询价收藏产品

加入购物车

到货通知，提交手机号入库后将短信通知。

产品描述：

EGFR-IN-47 is a potent and orally active EGFRL858R/T790M/C797S inhibitor with an IC50 of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC.

体外研究：

EGFR-IN-47 (compound 14aj) (72 h) shows anti-proliferative effects with IC50s of 0.013 μM, 2.972 μM, 1.031 μM for PC-9 (EGFRL858R/T790M/C797S), A432, A549 cells, respectively.
EGFR-IN-47 (0.01, 0.05, 0.25, 1 μM; 24 h) induces cell cycle attest at the G0/G1-phase.
EGFR-IN-47 (0.01, 0.05, 0.25 μM) induces cell deathvia apoptosis in a concentration-dependent manner.
EGFR-IN-47 (0.01, 0.05, 0.25, 1 μM) inhibits phosphorylation of the EGFR downstream mediators.

体内研究：

EGFR-IN-47 (10, 20, 40 mg/kg; i.g.) shows anti-tumor effect with low toxicity.
EGFR-IN-47 (20 mg/kg for i.v.; 20 mg/kg for p.o.) shows an ideal oral bioavailability of 66.05%.
Pharmacokinetic Parameters of JAK1/TYK2-IN-2 in Male Sprague-Dawley rats.

参考文献：

1. Wang C, et al. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. Eur J Med Chem. 2022; 237:114381.

保存条件：

-20°C

配置溶液浓度参考：

	1mg	5mg	10mg
1 mM	2.076 ml	10.381 ml	20.762 ml
5 mM	0.415 ml	2.076 ml	4.152 ml
10 mM	0.208 ml	1.038 ml	2.076 ml
50 mM	0.042 ml	0.208 ml	0.415 ml

注意：

部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

参考文献

质检证书(COA)

输入产品批号：

如何获取质检证书(COA)?

请输入货号和一个与之匹配的批号。
例如:
批号：JS298415 货号：S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

质量

浓度

体积

分子摩尔量

计算重置